173 related articles for article (PubMed ID: 19430392)
1. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
Gregori NZ; Gaitan J; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
Retina; 2008 Oct; 28(9):1325-37. PubMed ID: 19430392
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion.
Gregori NZ; Rattan GH; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
Retina; 2009; 29(7):913-25. PubMed ID: 19584649
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion.
Hung KH; Lee SM; Lee SY; Lee FL; Yang CS
J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
5. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
8. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.
Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U
Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.
Kriechbaum K; Michels S; Prager F; Georgopoulos M; Funk M; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Apr; 92(4):518-22. PubMed ID: 18211942
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
[TBL] [Abstract][Full Text] [Related]
20. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]